Profile data is unavailable for this security.
About the company
Chemclin Diagnostics Co Ltd is a China-based company mainly engaged in the research and development of clinical immuno chemiluminescence diagnostic test reagents and instruments. The Company's products are LiCA series of diagnostic reagents based on light-induced chemiluminescence and Chemclin series of diagnostic reagents and instruments based on enzymatic chemiluminescence, which are mainly used in infectious diseases (such as hepatitis B, hepatitis C, Acquired Immunodeficiency Syndrome, syphilis, hepatitis A, hepatitis E) detection of markers, tumor markers, thyroid hormones, reproductive endocrine hormones, diabetes, myocardial markers and inflammation. The Company mainly operates its businesses in the domestic market.
- Revenue in CNY (TTM)443.86m
- Net income in CNY139.29m
- Incorporated2007
- Employees731.00
- LocationChemclin Diagnostics Co LtdNo. 7 Fengxian M. Road, Haidian DistrictBEIJING 100094ChinaCHN
- Phone+86 1 058717511
- Fax+86 1 058717501
- Websitehttp://www.chemclin.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nanjing Medlander Medical Tech Co Ltd | 380.95m | 101.15m | 2.55bn | 481.00 | 24.92 | 1.95 | -- | 6.70 | 1.02 | 1.02 | 3.86 | 13.10 | 0.2527 | 1.98 | 21.47 | 791,989.40 | 7.06 | -- | 7.76 | -- | 71.46 | -- | 27.94 | -- | 7.57 | -- | 0.0115 | -- | -9.57 | -- | -26.19 | -- | -- | -- |
| Chemclin Diagnostics Co Ltd | 443.86m | 139.29m | 2.85bn | 731.00 | 20.45 | 2.04 | -- | 6.43 | 0.3476 | 0.3476 | 1.11 | 3.49 | 0.2491 | 1.00 | 16.34 | 607,195.30 | 7.82 | 11.01 | 8.73 | 12.32 | 74.89 | 74.19 | 31.38 | 31.07 | 5.16 | -- | 0.1515 | 36.64 | -4.28 | 4.00 | -3.44 | -- | 44.10 | -- |
| Cowealth Medical China Co Ltd | 970.41m | 29.67m | 2.90bn | 240.00 | 97.69 | 2.48 | -- | 2.99 | 0.0745 | 0.0745 | 2.44 | 2.93 | 0.6435 | 3.90 | 1.25 | 4,043,355.00 | 2.01 | 5.80 | 2.59 | 8.09 | 19.62 | 20.74 | 3.13 | 6.14 | 3.65 | -- | 0.0829 | 23.89 | -14.62 | 3.85 | -42.96 | -6.75 | 32.85 | -- |
| Nanjing Vishee Medical Technology Co Ltd | 422.21m | 112.74m | 2.90bn | 700.00 | 25.64 | 1.80 | -- | 6.87 | 1.18 | 1.18 | 4.42 | 16.83 | 0.2401 | 3.12 | 12.37 | 603,153.40 | 6.41 | 10.27 | 6.92 | 11.43 | 70.21 | 73.26 | 26.70 | 33.99 | 8.31 | -- | 0.0003 | 47.57 | 43.72 | 17.34 | 45.22 | 16.55 | 26.69 | -- |
| Beijing Succeeder Technology Inc | 297.74m | 112.75m | 2.94bn | 296.00 | 26.10 | 1.80 | -- | 9.86 | 1.06 | 1.06 | 2.80 | 15.41 | 0.1766 | 2.51 | 8.66 | 1,005,870.00 | 6.69 | 7.77 | 7.02 | 8.25 | 60.39 | 61.03 | 37.85 | 38.34 | 14.78 | -- | 0.00004 | 22.22 | 20.40 | 6.60 | 12.29 | 15.57 | 99.03 | -- |
| Beijing Hotgen Biotech Co Ltd | 520.50m | -67.64m | 2.98bn | 1.04k | -- | 0.9132 | -- | 5.72 | -0.7349 | -0.7349 | 5.74 | 35.25 | 0.1484 | 2.20 | 5.85 | 502,410.60 | -2.13 | 29.65 | -2.22 | 34.70 | 46.98 | 56.08 | -14.33 | 32.26 | 8.95 | -- | 0.0026 | 41.92 | -84.78 | 23.67 | -97.10 | -10.67 | 57.98 | -- |
| Hangzhou Biotest Biotech Co Ltd | 518.65m | 104.29m | 3.20bn | 629.00 | 30.27 | 1.35 | -- | 6.16 | 0.9897 | 0.9897 | 4.94 | 22.27 | 0.204 | 2.61 | 6.85 | 824,563.60 | 4.01 | 29.45 | 4.23 | 33.30 | 52.42 | 56.83 | 19.64 | 41.59 | 12.53 | -- | 0.0003 | 29.32 | -76.75 | 19.65 | -86.22 | 41.33 | 34.82 | -- |
Data as of Sep 13 2024. Currency figures normalised to Chemclin Diagnostics Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
2.36%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Yinhua Fund Management Co., Ltd.as of 30 Jun 2024 | 3.58m | 1.30% |
| China Asset Management Co., Ltd.as of 30 Jun 2024 | 1.37m | 0.50% |
| Maxwealth Fund Management Co., Ltd.as of 30 Jun 2024 | 537.20k | 0.20% |
| Bank of Communications Schroder Fund Management Co., Ltd.as of 30 Jun 2024 | 231.10k | 0.08% |
| Baoying Fund Management Co., Ltd.as of 30 Jun 2024 | 198.00k | 0.07% |
| Penghua Fund Management Co., Ltd.as of 30 Jun 2024 | 129.28k | 0.05% |
| Essence Fund Co., Ltd.as of 30 Jun 2024 | 126.52k | 0.05% |
| Hui'an Fund Management Co. Ltd.as of 30 Jun 2024 | 115.55k | 0.04% |
| GF Fund Management Co., Ltd.as of 30 Jun 2024 | 108.70k | 0.04% |
| Morgan Stanley Huaxin Fund Management Co., Ltd.as of 30 Jun 2024 | 101.20k | 0.04% |
More ▼
Data from 30 Jun 2024 - 27 Sep 2024Source: FactSet Research Systems Inc.
